The SMC's recommendation to advance to Cohort 2 is a positive de-risking signal for the SER-252 program, but data remain blinded and exploratory from a single low-dose cohort. Monitor for topline data from the full single-ascending-dose portion expected in H1 2027, which will be the next major catalyst. The company's ability to continue as a going concern is noted as a risk factor in the press release.
Price Chart
Executive Summary
Serina Therapeutics announced that the Independent Safety Monitoring Committee completed its blinded review of Cohort 1 of the Phase 1b registrational study of SER-252 in advanced Parkinson's disease and recommended advancement to Cohort 2. Blinded observations showed a sustained pharmacokinetic profile consistent with the drug's design and sustained motor function improvements in individual patients. Topline data from the single-ascending-dose portion is expected in the first half of 2027.
Key Facts
- Independent Safety Monitoring Committee recommended advancing SER-252 study to Cohort 2 after blinded review of Cohort 1 safety/tolerability data
- Cohort 1 evaluated the lowest dose in the single-ascending-dose portion of the Phase 1b registrational study
- Blinded observations showed a sustained pharmacokinetic profile consistent with prolonged apomorphine exposure
- Blinded observations included sustained periods of improvement in motor function in individual patients on exploratory clinical measures
- Topline data from the single-ascending-dose portion expected in the first half of 2027
- Cohort 1 enrolled eight patients with Parkinson's disease and motor fluctuations in a randomized, double-blind, placebo-controlled design
Financial Impact
No financial figures reported in the filing. Clinical-stage biotech with no revenue from SER-252.
Risk Factors
- Data are preliminary, blinded, and exploratory from a single low-dose cohort (n=8) and may not be predictive of future results
- Company's ability to continue as a going concern is explicitly noted as a risk factor
- Topline data not expected until first half of 2027, leaving a long period without catalysts
- Clinical-stage biotech with no approved products or revenue from SER-252
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001708599-26-000054 |
| Document: cohort1pr09032026_sredits.htm | 0001708599-26-000054 |
| Document: 0001708599-26-000054-index-headers.html | 0001708599-26-000054 |
| Document: 0001708599-26-000054-index.html | 0001708599-26-000054 |
| Document: 0001708599-26-000054.txt | 0001708599-26-000054 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $2.57 $2.16 | ▼ −15.95% | ▼ −14.86% | $1.55 (−39.67%) |
Jul 23, 2026 13w ago | Press Release | $2.09 $2.04 | ▼ −2.39% | ▼ −2.87% | $1.55 (−25.82%) |
Jul 22, 2026 13w ago | 8-K | $2.09 $2.04 | ▼ −2.39% | ▼ −2.87% | $1.55 (−25.82%) |
Jun 4, 2026 20w ago | EFFECT | $1.86 $1.81 | ▲ +2.69% | ▲ +0.14% | $1.55 (+16.65%) |
May 26, 2026 21w ago | Insider Cluster | $1.80 $1.79 | ▼ −0.56% | ▼ −1.02% | $1.55 (−13.87%) |
May 26, 2026 21w ago | Insider Cluster | $1.80 $1.79 | ▲ +0.56% | ▲ +1.02% | $1.55 (+13.87%) |
May 22, 2026 22w ago | S-3 | $1.92 $1.81 | ▲ +5.73% | ▲ +6.81% | $1.55 (+19.25%) |
Mar 27, 2026 30w ago | 10-K/A | $2.27 $2.15 | ▼ −5.29% | ▼ −9.15% | $1.55 (−31.70%) |
Mar 25, 2026 30w ago | Press Release | $2.61 $2.12 | ▼ −18.77% | ▼ −20.41% | $1.55 (−40.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers